Detecting Cancers Earlier Through Elective Plasma-based CancerSEEK Testing
Public ClinicalTrials.gov record NCT04213326. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Detecting Cancers Earlier Through Elective Plasma-based CancerSEEK Testing - Ascertaining Serial Cancer Patients to Enable New Diagnostic
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a prospective, observational study of 1,000 subjects with known or suspected cancer and 2,000 subjects with no known cancer. Potential participants will be asked questions to confirm their eligibility by a nurse navigator, study staff member, or physician. Informed consent will be carried out for eligible subjects in accordance with applicable federal regulations and International Council for Harmonisation (ICH)/Good Clinical Practice (GCP) guidelines. Subjects will then complete a survey, and study staff will draw 60 mL of blood and measure the height and weight of the subject. Where available, data from the medical records of the cancer subjects will reviewed and collected. In addition, non-cancer subjects will be requested to allow access to their medical records as an optional portion of their informed consent.
Study identification
- NCT ID
- NCT04213326
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 6,400 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 18, 2019 (Actual)
- Primary completion
- Jan 29, 2021 (Actual)
- Completion
- Jan 29, 2021 (Actual)
- Last update posted
- Jun 14, 2024
2019 – 2021
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sarah Cannon | Thousand Oaks | California | 23229 | — |
| Sarah Cannon | Denver | Colorado | 80220 | — |
| Sarah Cannon | Fort Walton Beach | Florida | 32547 | — |
| Sarah Cannon | Ocala | Florida | 34471 | — |
| Sarah Cannon | Pensacola | Florida | 32514 | — |
| Sarah Cannon | Augusta | Georgia | 30909 | — |
| Sarah Cannon | Macon | Georgia | 31217 | — |
| Sarah Cannon | Savannah | Georgia | 31404 | — |
| Sarah Cannon | Kansas City | Kansas | 64012 | — |
| Sarah Cannon | Overland Park | Kansas | 66209 | — |
| Sarah Cannon | Independence | Missouri | 64057 | — |
| Sarah Cannon | Las Vegas | Nevada | 89129 | — |
| Sarah Cannon | Nashville | Tennessee | 37203 | — |
| Sarah Cannon | Richmond | Virginia | 23229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04213326, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 14, 2024 · Synced Oct 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04213326 live on ClinicalTrials.gov.